Duration of anticoagulation of venous thromboembolism.

Venous thromboembolism (VTE) is a common, serious condition that requires anticoagulation for at least three months to prevent recurrence and long-term complications. After this initial period, the decision to continue or stop anticoagulation depends on the balance between the risk of recurrent VTE and the risk of bleeding. Established guidelines suggest short-term anticoagulation for VTE caused by transient factors and indefinite anticoagulation for recurrent or cancer-associated VTE. However, for a first unprovoked VTE, decision-making remains challenging. Current predictive scores for recurrence and bleeding are not sufficiently reliable, and the safety and efficacy of reduced-dose anticoagulation remain unclear. In the future, precision and patient-centred medicine may improve treatment decisions in this area.
Competing Interests: Declaration of competing interest Dr. Couturaud reports having received research grant support from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp and Dohme and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp and Dohme, GlaxoSmithKline, Chiesi and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp and Dohme, Leo Pharma, Sanofi, Chiesi. Dr.Morange reports having research grant support from Bristol-Myers Squibb and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer and Sanofi. Dr Sevestre reports fees and travel support from Bristol-Myers Squibb, Viatris, Leo Pharma and Novartis. Dr. Meneveau declares he has no conflict of interest.
(Copyright © 2024 Elsevier Masson SAS. All rights reserved.)